Cognition shares surge 21.56% intraday as Cognito Therapeutics partners with Ochsner Health on Alzheimer's Brain Health Collaboratory using the Spectris platform.

Cognition surged 21.56% intraday, as Cognito Therapeutics partnered with Ochsner Health to launch the Alzheimer's Brain Health Collaboratory, building a real-world disease progression and efficacy evaluation system around its Spectris platform. The company focuses on developing disease-modifying therapies for central nervous system and retinal degenerative diseases, with a pipeline of small-molecule drug candidates based on proprietary biology and chemistry platforms.